Online inquiry

IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2319MR)

This product GTTS-WQ2319MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD200 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001004196.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4345
UniProt ID P41217
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2319MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2869MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-761
GTTS-WQ462MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ10157MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ2892MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ4114MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ12045MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ5249MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ2338MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW